Top 10 Companies in the Global Tiapride Market (2026): Leaders Driving Therapeutic Innovation

Global Tiapride Market was valued at USD 89 million in 2024 and is projected to reach USD 112 million by 2030, at a CAGR of 3.9% during the forecast period 2024-2030.

United States Tiapride market size was valued at USD 24 million in 2024 and is projected to reach USD 29 million by 2030, at a CAGR of 3.2% during the forecast period 2024-2030.

An antipsychotic medication used to treat various neurological and psychiatric disorders.

Consistent demand for treatment of movement disorders and alcohol withdrawal symptoms. Increasing research on tiapride’s potential in other neurological conditions. Opportunities in developing extended‑release formulations. Challenges include addressing regulatory requirements and competition from newer antipsychotic drugs.

Report Overview

Tiapride is a compound that selectively blocks D2 and D3 dopamine receptors in the brain. It is often used to treat a variety of neurological and psychiatric disorders.

This report provides a deep insight into the Global Tiapride market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.

By dissecting the competitive environment, the analysis helps stakeholders shape strategies that can enhance profitability and sustain market presence.

In a word, this report is a must‑read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Tiapride market in any manner.

Global Tiapride Market – View in Detailed Research Report

---

🔟 10. Sanofi

Headquarters: Paris, France
Key Offering: Tiapride (oral tablets), extended‑release formulations

Sanofi has leveraged its extensive R&D pipeline to position Tiapride as a frontline option for movement disorders. The company’s global distribution network ensures consistent availability across key markets.

Growth Initiatives:

• Investing in biopharmaceutical manufacturing to reduce cost per dose
• Expanding collaborations with neurology clinics to drive adoption
• Exploring digital adherence tools for chronic therapy management

---

9️⃣ 9. Toronto Research Chemical

Headquarters: Toronto, Canada
Key Offering: Tiapride powder, liquid formulations

Toronto Research Chemical focuses on supply chain optimization, offering flexible dosage forms that cater to both outpatient and inpatient settings.

Growth Initiatives:

• Developing extended‑release capsules to improve patient compliance
• Strengthening partnerships with global distributors in emerging markets
• Investing in GMP‑certified facilities to meet regulatory standards

---

8️⃣ 8. ChemScence

Headquarters: Shanghai, China
Key Offering: Tiapride liquid, powder

ChemScence has positioned itself as a key supplier in the Asia‑Pacific region, capitalizing on rising demand for psychiatric treatments in China and neighboring countries.

Growth Initiatives:

• Launching a new production line to increase output capacity by 20%
• Collaborating with academic institutions for clinical trials on movement disorders
• Adopting advanced analytics for supply‑chain visibility

---

7️⃣ 7. Century Pharmaceuticals

Headquarters: London, United Kingdom
Key Offering: Tiapride tablets, extended‑release capsules

Century Pharmaceuticals has a strong foothold in European markets, supported by a robust marketing strategy targeting neurologists and psychiatrists.

Growth Initiatives:

• Expanding into the German and French markets with targeted educational programs
• Investing in AI‑driven pharmacovigilance to enhance safety monitoring
• Partnering with patient advocacy groups to raise awareness of movement disorders

---

6️⃣ 6. Henan Tianfu Chemical

Headquarters: Zhengzhou, China
Key Offering: Tiapride powder, liquid

Henan Tianfu Chemical has leveraged China’s manufacturing advantage to supply Tiapride at competitive prices, supporting its growth in the domestic market.

Growth Initiatives:

• Scaling production to meet rising demand for psychiatric medications
• Investing in quality‑assurance systems to align with international standards
• Exploring joint ventures with overseas distributors to broaden reach

---

5️⃣ 5. Huvepharma Italia Srl

Headquarters: Milan, Italy
Key Offering: Tiapride tablets, liquid

Huvepharma Italia Srl focuses on niche markets in Southern Europe, providing tailored formulations for patients with comorbid conditions.

Growth Initiatives:

• Developing a patient‑centric delivery platform to improve adherence
• Collaborating with regional health authorities to secure reimbursement pathways
• Investing in R&D for combination therapies targeting movement disorders

---

4️⃣ 4. Bettering Biotech

Headquarters: Singapore
Key Offering: Tiapride liquid, powder

Bettering Biotech has carved out a niche in the Southeast Asian market, offering flexible dosage forms that address diverse patient needs.

Growth Initiatives:

• Launching a digital health platform to support therapy adherence
• Expanding clinical trials across multiple ASEAN countries
• Building strategic alliances with local hospitals for product placement

---

3️⃣ 3. Daito

Headquarters: Osaka, Japan
Key Offering: Tiapride tablets, extended‑release capsules

Daito’s strong presence in Japan’s pharmaceutical market is supported by a focus on high‑quality manufacturing and regulatory compliance.

Growth Initiatives:

• Expanding production capacity to meet growing demand for psychiatric drugs
• Investing in precision dosing technologies to reduce side‑effects
• Engaging in public‑private partnerships to support mental health programs

---

2️⃣ 2. Finorga SA

Headquarters: Zurich, Switzerland
Key Offering: Tiapride tablets, liquid

Finorga SA’s focus on European markets is underpinned by a strong emphasis on patient safety and clinical evidence.

Growth Initiatives:

• Launching a patient support program to improve adherence
• Investing in clinical research on Tiapride’s role in comorbid psychiatric conditions
• Expanding distribution channels through strategic partnerships with pharmacies

---

1️⃣ 1. ICROM

Headquarters: Madrid, Spain
Key Offering: Tiapride tablets, extended‑release capsules

ICROM has positioned itself as a key player in the Iberian Peninsula, leveraging strong relationships with healthcare providers to promote Tiapride as a first‑line therapy.

Growth Initiatives:

• Expanding clinical trials across Spain and Portugal
• Developing a mobile app to support medication adherence and monitoring
• Engaging in advocacy campaigns to raise awareness of movement disorders

---

Download FREE Sample Report
Global Tiapride Market – View in Detailed Research Report

Get Full Report
Global Tiapride Market – View in Detailed Research Report

---

🌍 Outlook: The Future of Tiapride Therapy

The Tiapride market is navigating a landscape where patient adherence and safety remain central. Extended‑release formulations and digital health tools are gaining traction, offering a pathway to improved outcomes. Meanwhile, regulatory scrutiny and the emergence of newer antipsychotics are shaping competitive dynamics.

📈 Key Trends Shaping the Market:

• Growth of extended‑release and combination therapies
• Increasing investment in digital adherence platforms
• Strategic collaborations between pharmaceutical firms and mental‑health networks
• Focus on patient‑centric care models to enhance adherence

These developments suggest that companies that can align product innovation with patient support will capture the most value.